{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:09:53Z","timestamp":1792814993401,"version":"4.5.0"},"reference-count":148,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T00:00:00Z","timestamp":1659484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Medical University of Lodz, Poland","award":["503\/1-093-1\/503-81-001-19-00"],"award-info":[{"award-number":["503\/1-093-1\/503-81-001-19-00"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Cells must maintain their proteome homeostasis by balancing protein synthesis and degradation. This is facilitated by evolutionarily-conserved processes, including the unfolded protein response and the proteasome-based system of protein clearance, autophagy, and chaperone-mediated autophagy. In some hematological malignancies, including acute myeloid leukemia, misfolding or aggregation of the wild-type p53 tumor-suppressor renders cells unable to undergo apoptosis, even with an intact p53 DNA sequence. Moreover, blocking the proteasome pathway triggers lymphoma cell apoptosis. Extensive studies have led to the development of proteasome inhibitors, which have advanced into drugs (such as bortezomib) used in the treatment of certain hematological tumors, including multiple myeloma. New therapeutic options have been studied making use of the so-called proteolysis-targeting chimeras (PROTACs), that bind desired proteins with a linker that connects them to an E3 ubiquitin ligase, resulting in proteasomal-targeted degradation. This review examines the mechanisms of protein degradation in the cells of the hematopoietic system, explains the role of dysfunctional protein degradation in the pathogenesis of hematological malignancies, and discusses the current and future advances of therapies targeting these pathways, based on an extensive search of the articles and conference proceedings from 2005 to April 2022.<\/jats:p>","DOI":"10.3390\/cancers14153778","type":"journal-article","created":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T20:52:01Z","timestamp":1659559921000},"page":"3778","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Targeting Protein Degradation Pathways in Tumors: Focusing on their Role in Hematological Malignancies"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8838-2098","authenticated-orcid":false,"given":"Anna","family":"Wolska-Washer","sequence":"first","affiliation":[{"name":"Department of Experimental Hematology, Medical University of Lodz, 93-510 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Smolewski","sequence":"additional","affiliation":[{"name":"Department of Experimental Hematology, Medical University of Lodz, 93-510 Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1126\/science.1141448","article-title":"Adapting proteostasis for disease intervention","volume":"319","author":"Balch","year":"2008","journal-title":"Science"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/j.1742-4658.2011.08455.x","article-title":"Regulation of cellular protein quality control networks in a multicellular organism","volume":"279","author":"Kosolapov","year":"2012","journal-title":"FEBS J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1083\/jcb.201005144","article-title":"Protein homeostasis and aging in neurodegeneration","volume":"190","author":"Douglas","year":"2010","journal-title":"J. Cell Biol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"831116","DOI":"10.3389\/fnmol.2022.831116","article-title":"The Unfolded Protein Responses in Health, Aging, and Neurodegeneration: Recent Advances and Future Considerations","volume":"15","author":"Wodrich","year":"2022","journal-title":"Front. Mol. Neurosci."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/abbs\/gmab131","article-title":"Targeting UPR branches, a potential strategy for enhancing efficacy of cancer chemotherapy","volume":"53","author":"Yu","year":"2021","journal-title":"Acta Biochim. Biophys. Sin."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1016\/j.bbamcr.2013.05.018","article-title":"The role of phospholipids in the biological activity and structure of the endoplasmic reticulum","volume":"1833","author":"Lagace","year":"2013","journal-title":"Biochim. Biophys. Acta (BBA) Mol. Cell Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.devcel.2007.07.005","article-title":"ATF6alpha optimizes long-term endoplasmic reticulum function to protect cells from chronic stress","volume":"13","author":"Wu","year":"2007","journal-title":"Dev. Cell"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"C992","DOI":"10.1152\/ajpcell.00160.2011","article-title":"Pancreatic \u03b2-cells depend on basal expression of active ATF6\u03b1-p50 for cell survival even under nonstress conditions","volume":"302","author":"Teodoro","year":"2012","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1242\/jcs.045625","article-title":"ATF6alpha induces XBP1-independent expansion of the endoplasmic reticulum","volume":"122","author":"Bommiasamy","year":"2009","journal-title":"J. Cell Sci."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Siwecka, N., Rozp\u0119dek-Kami\u0144ska, W., Wawrzynkiewicz, A., Pytel, D., Diehl, J., and Majsterek, I. (2021). The Structure, Activation and Signaling of IRE1 and Its Role in Determining Cell Fate. Biomedicines, 9.","DOI":"10.3390\/biomedicines9020156"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.tibs.2018.06.005","article-title":"Quality Control in the Endoplasmic Reticulum: Crosstalk between ERAD and UPR pathways","volume":"43","author":"Hwang","year":"2018","journal-title":"Trends Biochem. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"747837","DOI":"10.3389\/fphar.2021.747837","article-title":"Targeting the Integrated Stress Response in Cancer Therapy","volume":"12","author":"Tian","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1038\/onc.2008.428","article-title":"PERK-dependent regulation of IAP translation during ER stress","volume":"28","author":"Hamanaka","year":"2009","journal-title":"Oncogene"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/ijo.2021.5201","article-title":"NUPR1 and its potential role in cancer and pathological conditions (Review)","volume":"58","author":"Martin","year":"2021","journal-title":"Int. J. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/978-1-0716-1975-9_1","article-title":"An Overview of Methods for Detecting eIF2\u03b1 Phosphorylation and the Integrated Stress Response","volume":"2428","author":"Krzyzosiak","year":"2022","journal-title":"Methods Mol. Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1101\/gad.1250704","article-title":"CHOP induces death by promoting protein synthesis and oxidation in the stressed endoplasmic reticulum","volume":"18","author":"Marciniak","year":"2004","journal-title":"Genes Dev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1128\/MCB.21.4.1249-1259.2001","article-title":"Gadd153 Sensitizes Cells to Endoplasmic Reticulum Stress by Down-Regulating Bcl2 and Perturbing the Cellular Redox State","volume":"21","author":"McCullough","year":"2001","journal-title":"Mol. Cell. Biol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.tibs.2015.01.002","article-title":"UPR, autophagy, and mitochondria crosstalk underlies the ER stress response","volume":"40","author":"Senft","year":"2015","journal-title":"Trends Biochem. Sci."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Lemus, L., and Goder, V. (2014). Regulation of Endoplasmic Reticulum-Associated Protein Degradation (ERAD) by Ubiquitin. Cells, 3.","DOI":"10.3390\/cells3030824"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1073\/pnas.1816596116","article-title":"N-degron and C-degron pathways of protein degradation","volume":"116","author":"Varshavsky","year":"2019","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Li, Y., Li, S., and Wu, H. (2022). Ubiquitination-Proteasome System (UPS) and Autophagy Two Main Protein Degradation Machineries in Response to Cell Stress. Cells, 11.","DOI":"10.3390\/cells11050851"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.trecan.2019.08.005","article-title":"DUBs, Hypoxia, and Cancer","volume":"5","author":"Mennerich","year":"2019","journal-title":"Trends Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1146\/annurev-biochem-062917-011931","article-title":"Structure and Function of the 26S Proteasome","volume":"87","author":"Bard","year":"2018","journal-title":"Annu. Rev. Biochem."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3389\/fmolb.2019.00040","article-title":"Dynamic regulation of the 26S proteasome: From synthesis to degradation","volume":"6","author":"Marshall","year":"2019","journal-title":"Front. Mol. Biosci."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Wang, J., Fang, Y., Fan, R.A., and Kirk, C.J. (2021). Proteasome Inhibitors and Their Pharmacokinetics, Pharmacodynamics, and Metabolism. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms222111595"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"6562","DOI":"10.1074\/jbc.RA118.006298","article-title":"Two alternative mechanisms regulate the onset of chaperone-mediated assembly of the proteasomal ATPases","volume":"294","author":"Nahar","year":"2019","journal-title":"J. Biol. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"21517","DOI":"10.1074\/jbc.M301032200","article-title":"Inhibition of proteasome activity induces concerted expression of proteasome genes and de novo formation of Mammalian proteasomes","volume":"278","author":"Meiners","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/jcb.21405","article-title":"Increased expression and altered subunit composition of proteasomes induced by continuous proteasome inhibition establish apoptosis resistance and hyperproliferation of Burkitt lymphoma cells","volume":"103","author":"Fuchs","year":"2008","journal-title":"J. Cell Biochem."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1042\/BCJ20160809","article-title":"Regulating Protein Breakdown Through Proteasome Phosphorylation","volume":"474","author":"VerPlank","year":"2017","journal-title":"Biochem. J."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"100233","DOI":"10.1074\/jbc.REV120.015217","article-title":"Emerging roles of DYRK2 in cancer","volume":"296","author":"Tandon","year":"2021","journal-title":"J. Biol. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1016\/j.celrep.2017.11.007","article-title":"TRIM48 Promotes ASK1 Activation and Cell Death through Ubiquitination-Dependent Degradation of the ASK1-Negative Regulator PRMT1","volume":"21","author":"Hirata","year":"2017","journal-title":"Cell Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nsmb.3389","article-title":"A mammalian nervous-system-specific plasma membrane proteasome complex that modulates neuronal function","volume":"24","author":"Ramachandran","year":"2017","journal-title":"Nat. Struct. Mol. Biol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"13266","DOI":"10.1073\/pnas.1616535113","article-title":"How the proteasome is degraded","volume":"113","author":"Hoeller","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_34","first-page":"E7490","article-title":"p62- and ubiquitin-dependent stress-induced autophagy of the mammalian 26S proteasome","volume":"113","author":"Livneh","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Shin, J.Y., Muniyappan, S., Tran, N.N., Park, H., Lee, S.B., and Lee, B.H. (2020). Deubiquitination Reactions on the Proteasome for Proteasome Versatility. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21155312"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Ziegler, D.V., Huber, K., and Fajas, L. (2021). The Intricate Interplay between Cell Cycle Regulators and Autophagy in Cancer. Cancers, 14.","DOI":"10.3390\/cancers14010153"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1042\/EBC20160005","article-title":"Cellular proteostasis: Degradation of misfolded proteins by lysosomes","volume":"60","author":"Jackson","year":"2016","journal-title":"Essays Biochem."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nature11895","article-title":"FOXO3A directs a protective autophagy program in haematopoietic stem cells","volume":"494","author":"Warr","year":"2013","journal-title":"Nature"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1084\/jem.20101145","article-title":"The autophagy protein Atg7 is essential for hematopoietic stem cell maintenance","volume":"208","author":"Mortensen","year":"2011","journal-title":"J. Exp. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s11684-010-0210-7","article-title":"Molecular mechanisms of leukemia-associated protein degradation","volume":"4","author":"Wu","year":"2010","journal-title":"Front. Med. China"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1182\/blood-2010-01-261040","article-title":"Autophagy contributes to therapy-induced degradation of the PML\/RARA oncoprotein","volume":"116","author":"Isakson","year":"2010","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1038\/sj.leu.2404319","article-title":"Ubiquitylation in normal and malignant hematopoiesis: Novel therapeutic targets","volume":"20","author":"Marteijn","year":"2006","journal-title":"Leukemia"},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Zhang, J., Wu, K., Xiao, X., Liao, J., Hu, Q., Chen, H., Liu, J., and An, X. (2015). Autophagy as a Regulatory Component of Erythropoiesis. Int. J. Mol. Sci., 16.","DOI":"10.3390\/ijms16024083"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1182\/blood-2008-09-115238","article-title":"Chaperoning erythropoiesis","volume":"113","author":"Weiss","year":"2009","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1111\/febs.13962","article-title":"Mechanistic roles of autophagy in hematopoietic differentiation","volume":"284","author":"Riffelmacher","year":"2017","journal-title":"FEBS J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/ni.3025","article-title":"Autophagy is essential for effector CD8(+) T cell survival and memory formation","volume":"15","author":"Xu","year":"2014","journal-title":"Nat. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/icb.2014.81","article-title":"Autophagy in T-cell development, activation and differentiation","volume":"93","author":"Bronietzki","year":"2015","journal-title":"Immunol. Cell Biol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.4049\/jimmunol.1002223","article-title":"A role for autophagic protein beclin 1 early in lymphocyte development","volume":"186","author":"Arsov","year":"2011","journal-title":"J. Immunol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/ni.2524","article-title":"Plasma cells require autophagy for sustainable immunoglobulin production","volume":"14","author":"Pengo","year":"2013","journal-title":"Nat. Immunol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"192","DOI":"10.4161\/auto.26927","article-title":"Review Article: Autophagy-mediated regulation of macrophages and its applications for cancer","volume":"10","author":"Chen","year":"2014","journal-title":"Autophagy"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/nrd4389","article-title":"Drugging the undruggable RAS: Mission Possible?","volume":"13","author":"Cox","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/0092-8674(91)90124-H","article-title":"Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes","volume":"66","author":"Liu","year":"1991","journal-title":"Cell"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cell.2020.12.020","article-title":"The Rise of Molecular Glues","volume":"184","author":"Schreiber","year":"2021","journal-title":"Cell"},{"key":"ref_54","first-page":"1","article-title":"Clinical considerations for the design of PROTACs in cancer","volume":"21","author":"Morafraile","year":"2022","journal-title":"Mol. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1158\/2159-8290.CD-21-0260","article-title":"Emerging Trends in Cancer Drug Discovery\u2014From Drugging the \u201cUndruggable\u201d to Overcoming Resistance","volume":"11","author":"Rudolph","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1016\/j.jmb.2017.08.008","article-title":"RING-Between-RING E3 Ligases: Emerging Themes amid the Variations","volume":"429","author":"Dove","year":"2017","journal-title":"J. Mol. Biol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1242\/jcs.091777","article-title":"HECT and RING finger families of E3 ubiquitin ligases at a glance","volume":"125","author":"Metzger","year":"2012","journal-title":"J. Cell Sci."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"33111","DOI":"10.1074\/jbc.M102755200","article-title":"U box proteins as a new family of ubiquitin-protein ligases","volume":"276","author":"Hatakeyama","year":"2001","journal-title":"J. Biol. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1146\/annurev.biochem.78.101807.093809","article-title":"RING domain E3 ubiquitin ligases","volume":"78","author":"Deshaies","year":"2009","journal-title":"Annu. Rev. Biochem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"100020","DOI":"10.1016\/j.crchbi.2022.100020","article-title":"Expanding the landscape of E3 ligases for targeted protein degradation","volume":"2","author":"Kramer","year":"2022","journal-title":"Curr. Res. Chem. Biol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/nature16979","article-title":"Structural basis of lenalidomide-induced CK1\u03b1 degradation by the CRL4CRBN ubiquitin ligase","volume":"532","author":"Petzold","year":"2016","journal-title":"Nature"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/nature13527","article-title":"Structure of the DDB1\u2013CRBN E3 ubiquitin ligase in complex with thalidomide","volume":"512","author":"Fischer","year":"2014","journal-title":"Nature"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"113749","DOI":"10.1016\/j.ejmech.2021.113749","article-title":"Developments of CRBN-based PROTACs as potential therapeutic agents","volume":"225","author":"Wang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-021-01146-7","article-title":"Protein degradation technology: A strategic paradigm shift in drug discovery","volume":"14","author":"Li","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_65","first-page":"439","article-title":"A Review of the Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies","volume":"12","author":"Moore","year":"2021","journal-title":"J. Adv. Pract. Oncol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11523-021-00864-9","article-title":"Correction to: Bruton Tyrosine Kinase Inhibitors in B-Cell Malignancies: Their Use and Differential Features","volume":"17","author":"Shirley","year":"2022","journal-title":"Target. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Profit\u00f3s-Pelej\u00e0, N., Santos, J.C., Mar\u00edn-Niebla, A., Rou\u00e9, G., and Ribeiro, M.L. (2022). Regulation of B-Cell Receptor Signaling and Its Therapeutic Relevance in Aggressive B-Cell Lymphomas. Cancers, 14.","DOI":"10.3390\/cancers14040860"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1080\/17474086.2022.2054800","article-title":"Acalabrutinib: A bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia","volume":"15","author":"Robak","year":"2022","journal-title":"Expert Rev. Hematol."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Robak, T., Witkowska, M., and Smolewski, P. (2022). The Role of Bruton\u2019s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future Directions. Cancers, 14.","DOI":"10.3390\/cancers14030771"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"e233","DOI":"10.3747\/co.26.4345","article-title":"Review of bruton tyrosine kinase inhibitors for the treatment of relapsed or refractory mantle cell lymphoma","volume":"26","author":"Owen","year":"2019","journal-title":"Curr. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-021-01049-7","article-title":"Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies","volume":"14","author":"Gu","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"E7285","DOI":"10.1073\/pnas.1803662115","article-title":"Delineating the role of cooperativity in the design of potent PROTACs for BTK","volume":"115","author":"Zorba","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.4049\/jimmunol.1301553","article-title":"Selective Inhibition of BTK Prevents Murine Lupus and Antibody-Mediated Glomerulonephritis","volume":"191","author":"Rankin","year":"2013","journal-title":"J. Immunol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12918-017-0447-8","article-title":"Cooperative binding mitigates the high-dose hook effect","volume":"11","author":"Roy","year":"2017","journal-title":"BMC Syst. Biol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.chembiol.2017.10.005","article-title":"A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degrader","volume":"25","author":"Huang","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3564","DOI":"10.1021\/acs.biochem.8b00391","article-title":"Targeting the C481S Ibrutinib-Resistance Mutation in Bruton\u2019s Tyrosine Kinase Using PROTAC-Mediated Degradation","volume":"57","author":"Buhimschi","year":"2018","journal-title":"Biochemistry"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"672267","DOI":"10.3389\/fchem.2021.672267","article-title":"From Conception to Development: Investigating PROTACs Features for Improved Cell Permeability and Successful Protein Degradation","volume":"9","author":"Cecchini","year":"2021","journal-title":"Front. Chem."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood-2020-141461","article-title":"Nx-2127, a Degrader of BTK and IMiD Neosubstrates, for the Treatment of B-Cell Malignancies","volume":"136","author":"Robbins","year":"2020","journal-title":"Blood"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1038\/s41422-018-0055-1","article-title":"PROTAC-induced BTK degradation as a novel therapy for mutated BTK C481S induced ibrutinib-resistant B-cell malignancies","volume":"28","author":"Sun","year":"2018","journal-title":"Cell Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1038\/s41375-019-0440-x","article-title":"Degradation of Bruton\u2019s tyrosine kinase mutants by PROTACs for potential treatment of ibrutinib-resistant non-Hodgkin lymphomas","volume":"33","author":"Sun","year":"2019","journal-title":"Leukemia"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1039\/C9CC08238G","article-title":"Protein degradation through covalent inhibitor-based PROTACs","volume":"56","author":"Xue","year":"2020","journal-title":"Chem. Commun."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1038\/s41591-019-0668-z","article-title":"A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity","volume":"25","author":"Khan","year":"2019","journal-title":"Nat Med."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Morales-Mart\u00ednez, M., and Vega, M.I. (2022). Roles and Regulation of BCL-xL in Hematological Malignancies. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23042193"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1182\/blood-2011-04-347849","article-title":"Bcl-xL-inhibitory BH3 mimetics can induce a transient thrombocytopathy that undermines the hemostatic function of platelets","volume":"118","author":"Schoenwaelder","year":"2011","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-020-00928-9","article-title":"DT2216\u2014A Bcl-xL-specific degrader is highly active against Bcl-xL-dependent T cell lymphomas","volume":"13","author":"He","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/j.1600-065X.2012.01112.x","article-title":"Roles of BCL6 in normal and transformed germinal center B cells","volume":"247","author":"Basso","year":"2012","journal-title":"Immunol. Rev."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/nature03147","article-title":"The BCL6 proto-oncogene suppresses p53 expression in germinal-centre B cells","volume":"432","author":"Phan","year":"2004","journal-title":"Nature"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1586\/17474086.2013.826928","article-title":"Targeting Bcl-6 in diffuse large B-cell lymphoma: What does this mean for the future treatment?","volume":"6","author":"Cerchietti","year":"2013","journal-title":"Expert Rev. Hematol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.hoc.2019.04.001","article-title":"Burkitt Lymphoma and Other High-Grade B-Cell Lymphomas with or without MYC, BCL2, and\/or BCL6 Rearrangements","volume":"33","author":"Alsharif","year":"2019","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21037\/aol.2018.12.02","article-title":"Aggressive B-cell lymphomas\u2014from morphology to molecular pathogenesis","volume":"3","author":"Chen","year":"2019","journal-title":"Ann. Lymphoma"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1111\/his.13286","article-title":"Aberrant expression of CD10 and BCL6 in mantle cell lymphoma","volume":"71","author":"Pizzi","year":"2017","journal-title":"Histopathology"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1021\/acschembio.8b00698","article-title":"Development of a Novel B-Cell Lymphoma 6 (BCL6) PROTAC to Provide Insight into Small Molecule Targeting of BCL6","volume":"13","author":"McCoull","year":"2018","journal-title":"ACS Chem. Biol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1016\/j.celrep.2017.08.081","article-title":"Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6","volume":"20","author":"Kerres","year":"2017","journal-title":"Cell Rep."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"4047","DOI":"10.1021\/acs.jmedchem.9b02076","article-title":"Achieving in Vivo Target Depletion through the Discovery and Optimization of Benzimidazolone BCL6 Degraders","volume":"63","author":"Bellenie","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/s41586-020-2925-1","article-title":"Small molecule-induced polymerization triggers degradation of BCL6","volume":"588","author":"Yoon","year":"2020","journal-title":"Nature"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1002\/ajh.26523","article-title":"Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments","volume":"97","author":"Jain","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"787","DOI":"10.3389\/fmolb.2021.728777","article-title":"The Functions of BET Proteins in Gene Transcription of Biology and Diseases","volume":"8","author":"Cheung","year":"2021","journal-title":"Front. Mol. Biosci."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Taniguchi, Y. (2016). The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins. Int. J. Mol. Sci., 17.","DOI":"10.20944\/preprints201610.0100.v1"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/blood-2015-04-639542","article-title":"Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib","volume":"126","author":"Sun","year":"2015","journal-title":"Blood"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/leu.2017.207","article-title":"BET protein proteolysis targeting chimera (PROTAC) exerts potent lethal activity against mantle cell lymphoma cells","volume":"32","author":"Sun","year":"2018","journal-title":"Leukemia"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nature10334","article-title":"RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia","volume":"478","author":"Zuber","year":"2011","journal-title":"Nature"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1038\/leu.2016.393","article-title":"Novel BET protein Proteolysis Targeting Chimera (BET-PROTAC) exerts superior lethal activity than Bromodomain Inhibitor (BETi) against post-myeloproliferative Neoplasm (MPN) Secondary (s) AML Cells","volume":"31","author":"Saenz","year":"2017","journal-title":"Leukemia"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"106156","DOI":"10.1016\/j.phrs.2022.106156","article-title":"Targeting BCR-Abl in the treatment of Philadelphia-chromosome positive chronic myelogenous leukemia","volume":"178","author":"Roskoski","year":"2022","journal-title":"Pharm. Res."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1634\/theoncologist.2013-0077","article-title":"Food and Drug Administration approval summary: Omacetaxine mepesuccinate as treatment for chronic myeloid leukemia","volume":"19","author":"Alvandi","year":"2014","journal-title":"Oncologist"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"4744","DOI":"10.1158\/0008-5472.CAN-19-1236","article-title":"Targeting BCR-ABL1 in Chronic Myeloid Leukemia by PROTAC-mediated Targeted Protein Degradation","volume":"79","author":"Burslem","year":"2019","journal-title":"Cancer Res."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1021\/acs.jmedchem.9b02083","article-title":"Discovery of Selective Small Molecule Degraders of BRAF-V600E","volume":"63","author":"Han","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1517\/13543784.2015.1081895","article-title":"Potential breakthroughs with investigational drugs for hairy cell leukemia","volume":"24","author":"Robak","year":"2015","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41467-021-21159-7","article-title":"Mutant-selective degradation by BRAF-targeting PROTACs","volume":"12","author":"Alabi","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"821344","DOI":"10.3389\/fphar.2022.821344","article-title":"JAK\/STAT Signaling: Molecular Targets, Therapeutic Opportunities, and Limitations of Targeted Inhibitions in Solid Malignancies","volume":"13","author":"Rah","year":"2022","journal-title":"Front. Pharmacol."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Arora, L., Kumar, A., Arfuso, F., Chng, W., and Sethi, G. (2018). The Role of Signal Transducer and Activator of Transcription 3 (STAT3) and Its Targeted Inhibition in Hematological Malignancies. Cancers, 10.","DOI":"10.3390\/cancers10090327"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ccell.2019.10.002","article-title":"A Potent and Selective Small-molecule Degrader of STAT3 Achieves Complete Tumor Regression in vivo","volume":"36","author":"Bai","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.08.001","article-title":"Hematopoietic Progenitor Kinase1 (HPK1) Mediates T Cell Dysfunction and Is a Druggable Target for T Cell-Based Immunotherapies","volume":"38","author":"Si","year":"2020","journal-title":"Cancer Cell"},{"key":"ref_113","first-page":"2339","article-title":"PD-1\/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy","volume":"12","author":"Liu","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"86","DOI":"10.3389\/fonc.2018.00086","article-title":"Anti-PD-1 and anti-CTLA-4 therapies in cancer: Mechanisms of action, efficacy, and limitations","volume":"8","author":"Seidel","year":"2018","journal-title":"Front. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-021-00518-z","article-title":"Latest advances in the management of classical Hodgkin lymphoma: The era of novel therapies","volume":"11","author":"Mohty","year":"2021","journal-title":"Blood Cancer J."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1158\/1535-7163.MCT-18-1129","article-title":"Acquired resistance to BET-PROTACs caused by genomic alterations in core components of E3 ligase complexes","volume":"18","author":"Zhang","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1038\/nchembio.2329","article-title":"Structural basis of PROTAC cooperative recognition for selective protein degradation","volume":"13","author":"Gadd","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"639176","DOI":"10.3389\/fchem.2021.639176","article-title":"Photopharmacology of Proteolysis-Targeting Chimeras: A New Frontier for Drug Discovery","volume":"9","author":"Zeng","year":"2021","journal-title":"Front. Chem."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"8942","DOI":"10.1073\/pnas.1217206110","article-title":"Posttranslational protein knockdown coupled to receptor tyrosine kinase activation with phosphoPROTACs","volume":"110","author":"Hines","year":"2013","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1021\/acschembio.5b00442","article-title":"HaloPROTACS: Use of Small Molecule PROTACs to Induce Degradation of HaloTag Fusion Proteins","volume":"10","author":"Buckley","year":"2015","journal-title":"ACS Chem. Biol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41467-017-00954-1","article-title":"Homo-PROTACs: Bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to induce self-degradation","volume":"8","author":"Maniaci","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ddtec.2018.12.002","article-title":"SNIPERs\u2014Hijacking IAP activity to induce protein degradation","volume":"31","author":"Naito","year":"2019","journal-title":"Drug Discov. Today: Technol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/leu.2014.56","article-title":"Inhibitor of Apoptosis (IAP) proteins in hematological malignancies: Molecular mechanisms and therapeutic opportunities","volume":"28","author":"Fulda","year":"2014","journal-title":"Leukemia"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1111\/cas.13284","article-title":"Development of protein degradation inducers of oncogenic BCR-ABL protein by conjugation of ABL kinase inhibitors and IAP ligands","volume":"108","author":"Shibata","year":"2017","journal-title":"Cancer Sci."},{"key":"ref_125","first-page":"1492","article-title":"Development of hybrid small molecules that induce degradation of estrogen receptor-alpha and necrotic cell death in breast cancer cells","volume":"104","author":"Okuhira","year":"2013","journal-title":"Wiley Online Libr."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"112397","DOI":"10.1016\/j.ejmech.2020.112397","article-title":"Discovery of IAP-Recruiting BCL-XL PROTACs as Potent Degraders across Multiple Cancer Cell Lines","volume":"199","author":"Zhang","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1248\/cpb.c18-00703","article-title":"Development of a Potent Protein Degrader against Oncogenic BCR-ABL Protein","volume":"67","author":"Shibata","year":"2019","journal-title":"Chem. Pharm. Bull."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1074\/jbc.R117.818237","article-title":"Chaperone-mediated autophagy and endosomal microautophagy: Jointed by a chaperone","volume":"293","author":"Tekirdag","year":"2018","journal-title":"J. Biol. Chem."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"18492","DOI":"10.1523\/JNEUROSCI.3219-11.2011","article-title":"Constitutive upregulation of chaperone-mediated autophagy in Huntington\u2019s disease","volume":"31","author":"Koga","year":"2011","journal-title":"J. Neurosci."},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Andrade-Tomaz, M., De Souza, I., Rocha, C.R.R., and Gomes, L.R. (2020). The Role of Chaperone-Mediated Autophagy in Cell Cycle Control and Its Implications in Cancer. Cells, 9.","DOI":"10.3390\/cells9092140"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1083\/jcb.201503044","article-title":"Degradation of HK2 by chaperone-mediated autophagy promotes metabolic catastrophe and cell death","volume":"210","author":"Xia","year":"2015","journal-title":"J. Cell Biol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1038\/s41375-018-0336-1","article-title":"LAMP2 expression dictates azacytidine response and prognosis in MDS\/AML","volume":"33","author":"Dubois","year":"2019","journal-title":"Leukemia"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1080\/15548627.2019.1586259","article-title":"Azacitidine resistance caused by LAMP2 deficiency: A therapeutic window for the use of autophagy inhibitors in MDS\/AML patients?","volume":"15","author":"Robert","year":"2019","journal-title":"Autophagy"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.yexcr.2014.05.013","article-title":"Degradation of AF1Q by chaperone-mediated autophagy","volume":"327","author":"Li","year":"2014","journal-title":"Exp. Cell Res."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1101\/gad.220897.113","article-title":"Chaperone-mediated autophagy degrades mutant p53","volume":"27","author":"Kim","year":"2013","journal-title":"Genes Dev."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.tips.2020.04.005","article-title":"Emerging New Concepts of Degrader Technologies","volume":"41","author":"Ding","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s42004-020-00397-8","article-title":"Extracellular protein degradation via the lysosome","volume":"3","author":"Eldeeb","year":"2020","journal-title":"Commun. Chem."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/s41586-020-2545-9","article-title":"Lysosome-targeting chimaeras for degradation of extracellular proteins","volume":"584","author":"Banik","year":"2020","journal-title":"Nature"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1038\/s41589-021-00770-1","article-title":"LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation","volume":"17","author":"Ahn","year":"2021","journal-title":"Nat. Chem. Biol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41589-021-00851-1","article-title":"Bifunctional small molecules that mediate the degradation of extracellular proteins","volume":"17","author":"Caianiello","year":"2021","journal-title":"Nat. Chem. Biol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/s41467-022-28520-4","article-title":"The AUTOTAC chemical biology platform for targeted protein degradation via the autophagy-lysosome system","volume":"13","author":"Ji","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.molcel.2019.09.009","article-title":"AUTACs: Cargo-Specific Degraders Using Selective Autophagy","volume":"76","author":"Takahashi","year":"2019","journal-title":"Mol. Cell"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/s41589-019-0421-4","article-title":"Discovery of a first-in-class EZH2 selective degrader","volume":"16","author":"Ma","year":"2020","journal-title":"Nat. Chem. Biol."},{"key":"ref_144","doi-asserted-by":"crossref","unstructured":"Rinke, J., Chase, A., Cross, N.C.P., Hochhaus, A., and Ernst, T. (2020). EZH2 in Myeloid Malignancies. Cells, 9.","DOI":"10.3390\/cells9071639"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.yexmp.2018.07.009","article-title":"EZH2 is upregulated in the proliferation centers of CLL\/SLL lymph nodes","volume":"105","author":"Csala","year":"2018","journal-title":"Exp. Mol. Pathol."},{"key":"ref_146","first-page":"1415","article-title":"Clinical significance of enhancer of zeste homolog 2 and histone deacetylases 1 and 2 expression in peripheral T-cell lymphoma","volume":"18","author":"Zhang","year":"2019","journal-title":"Oncol. Lett."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"530","DOI":"10.20892\/j.issn.2095-3941.2018.0380","article-title":"Targeting EZH1\/2 induces cell cycle arrest and inhibits cell proliferation through reactivation of p57 CDKN1C and TP53INP1 in mantle cell lymphoma","volume":"16","author":"Li","year":"2019","journal-title":"Cancer Biol. Med."},{"key":"ref_148","first-page":"27","article-title":"Morphoproteomics Identifies SIRT1, EZH2 and CXCR4 Pathways in Diffuse Large B-Cell Lymphoma: Therapeutic Implications","volume":"52","author":"Brown","year":"2022","journal-title":"Ann. Clin. Lab. Sci."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/15\/3778\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:03:38Z","timestamp":1760141018000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/15\/3778"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,3]]},"references-count":148,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["cancers14153778"],"URL":"https:\/\/doi.org\/10.3390\/cancers14153778","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,3]]}}}